SCHEMBL4452324

SCHEMBL4452324

CCC=CCC=CCC=CCC=CCC=CCCCCC(=O)O

nearest known ligand 0.96

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.96
PPARG P37231 8/20 0.96
F7 P08709 7/20 0.96
F3 P13726 7/20 0.96
CYP19A1 P11511 6/20 0.96
PPARD Q03181 6/20 0.96
PPARA Q07869 6/20 0.96
PTGS1 P23219 5/20 0.96
FFAR1 O14842 5/20 0.96
MAPT P10636 4/20 0.96
OXER1 Q8TDS5 4/20 0.96
KMT2A Q03164 3/20 0.96
L3MBTL1 Q9Y468 3/20 0.96
KDM4E B2RXH2 3/20 0.96
LMNA P02545 3/20 0.96
CYP3A4 P08684 3/20 0.96
HPGD P15428 3/20 0.96
ALOX15 P16050 3/20 0.96
HSD17B10 Q99714 3/20 0.96
TDP1 Q9NUW8 3/20 0.96

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL606016 1.00 ALDH1A1 (0.96) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL7750567 1.00 ALDH1A1 (0.96) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL452559 1.00 ALDH1A1 (0.96) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL454567 1.00 ALDH1A1 (0.96) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL10444556 1.00 ALDH1A1 (0.96) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL7755119 1.00 ALDH1A1 (0.96) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL14119798 1.00 ALDH1A1 (0.96) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL7750573 1.00 ALDH1A1 (0.96) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL15994740 1.00 ALDH1A1 (0.96) ALDH1A1PPARGF7F3CYP19A1
SCHEMBL29226 1.00 ALDH1A1 (0.96) ALDH1A1PPARGF7F3CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024141286-A1 (METH)ACRYLATED ISOCYANURATE MIXTURE, PROCESS FOR PREPARING SAME, AND USES THEREOF ARKEMA FRANCE (FR) 2024-07-04 WO claimed
CN-112996500-A Compositions and methods for modulating ELOVL2 优美佳生物技术有限公司 2021-06-18 CN claimed
EP-3806840-A1 COMPOSITION AND METHODS FOR MODULATION OF ELOVL2 Youhealth Biotech, Limited (KY) 2021-04-21 EP claimed
US-10125078-B1 NSAID derivatives of omega-3 polyunsaturated acids as gamma secretase modulators JIVA PHARMA INC. (US) 2018-11-13 US claimed
US-9688613-B2 Omegabalins, GABA derivatives of omega-3 polyunsaturated acids, their formulations and methods of use JIVA PHARMA, INC. (US) 2017-06-27 US claimed
US-9540307-B2 Statins of omega-3 polyunsaturated acids for treating hypercholesterolemia JIVA PHARMA, INC. (US) 2017-01-10 US claimed
US-20160376223-A1 Omegabalins, GABA Derivatives of Omega-3 Polyunsaturated Acids, Their Formulations and Methods of Use JIVA PHARMA, INC. (US) 2016-12-29 US claimed
US-9364465-B2 Thiazolidinediones of omega-3 polyunsaturated acids as new insulin sensitizers for treating type2 diabetes Jiva Pharma, Inc (US) 2016-06-14 US claimed
US-20160051521-A1 Thiazolidinediones of Omega-3 Polyunsaturated Acids as New Insulin Sensitizers for Treating Type2 Diabetes JIVA PHARMA, INC. (US) 2016-02-25 US claimed
US-20150374660-A1 Ascorbate Esters of Omega-3 Fatty Acids and Their Formulations and Uses JIVA PHARMA, INC. (US) 2015-12-31 US claimed
US-20150344402-A1 Omefibrates for Treating Dyslipidemia and Cardiovascular Disease JIVA PHARMA, INC. (US) 2015-12-03 US claimed
US-20150322032-A1 Statins of Omega-3 Polyunsaturated Acids for Treating Hypercholesterolemia JIVA PHARMA, INC. (US) 2015-11-12 US claimed
WO-2014160936-A2 THIAZOLIDINEDIONES OF OMEGA-3 POLYUNSATURATED ACIDS AS NEW INSULIN SENSITIZERS FOR TREATING TYPE2 DIABETES JIVA PHARMA, INC. (US) 2014-10-02 WO claimed
WO-2014134053-A1 ASCORBATE ESTERS OF OMEGA-3 FATTY ACIDS JIVA PHARMA, INC. (US) 2014-09-04 WO claimed
EP-1888727-A1 NEW DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS Pronova BioPharma Norge AS (NO) 2008-02-20 EP claimed
EP-1888728-A1 FATTY ACID ANALOGUES, I.E. DHA DERIVATIVES FOR USES AS A MEDICAMENT Pronova BioPharma Norge AS (NO) 2008-02-20 EP claimed
WO-2006117668-A1 FATTY ACID ANALOGUES, I.E. DHA DERIVATIVES FOR USES AS A MEDICAMENT PRONOVA BIOPHARMA NORGE AS (NO) 2006-11-09 WO claimed
WO-2006117664-A1 NEW DHA DERIVATIVES AND THEIR USE AS MEDICAMENTS PRONOVA BIOPHARMA NORGE AS (SE) 2006-11-09 WO claimed
US-20250388720-A1 ALKYD EMULSION HAVING IMPROVED WATER RESISTANCE AND IMPROVED HARDNESS DEVELOPMENT ARKEMA FRANCE (FR) 2025-12-25 US disclosed
US-5698594-A ADMINISTERING MIXTURE OF ALL-Z OMEGA-3 FATTY ACIDS INCLUDING 5,8,11,14,17-EICOSAPENTAENOIC ACID, 4,7,10,13,16,19-DOCOSAHEXAENOIC ACID, 6,9,12,15,18-HENEICOSAPENTAENOIC ACID NORSK HYDRO A.S (NO) 1997-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160051521-A1 Thiazolidinediones of Omega-3 Polyunsaturated Acids as New Insulin Sensitizers for Treating Type2 Diabetes PPARD, PPARA, PPARG ALDH1A1 2213/4885PPARG 3/4885F7 4550/4885
US-20150344402-A1 Omefibrates for Treating Dyslipidemia and Cardiovascular Disease PPARA, PPARG, PPARD ALDH1A1 2441/4885PPARG 2/4885F7 4412/4885
US-20150374660-A1 Ascorbate Esters of Omega-3 Fatty Acids and Their Formulations and Uses ELOVL3, LIPA, LIPC ALDH1A1 213/4885PPARG 568/4885F7 1033/4885
US-10125078-B1 NSAID derivatives of omega-3 polyunsaturated acids as gamma secretase modulators PTGES3, PTGES, PTGER3 ALDH1A1 2346/4885PPARG 108/4885F7 4816/4885
US-20160376223-A1 Omegabalins, GABA Derivatives of Omega-3 Polyunsaturated Acids, Their Formulations and Methods of Use GABRB3, GABRA3, GABRA5 ALDH1A1 1812/4885PPARG 228/4885F7 1076/4885
US-20250388720-A1 ALKYD EMULSION HAVING IMPROVED WATER RESISTANCE AND IMPROVED HARDNESS DEVELOPMENT DRD1, DRD2, DRD3 ALDH1A1 200/4885PPARG 1669/4885F7 2051/4885
US-20150322032-A1 Statins of Omega-3 Polyunsaturated Acids for Treating Hypercholesterolemia HMGCR, ELOVL3, STARD3 ALDH1A1 3793/4885PPARG 122/4885F7 3615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.